pre-IPO PHARMA

COMPANY OVERVIEW

ILC Therapeutics Ltd is an early stage biotechnology company focused on modulating the Innate Immune System through the development of novel peptide therapeutics for the treatment of Cancer, Atopic Dermatitis, Psoriasis and Allergic Asthma amongst other conditions. More recently however, ILC Therapeutics has discovered that its ongoing research has potential to treat COVID-19.


LOCATION

  • Lanarkshire, Scotland, UK

  • THERAPEUTIC AREAS

  • Autoimmune Disease
  • Infectious Disease
  • Inflammatory Disease
  • Oncology

  • WEBSITE

    https://www.ilctherapeutics.com/


    CAREER WEBSITE

    None


    SOCIAL MEDIA


    INVESTORS



    PRESS RELEASES


    May 23, 2023

    Scottish Biotech ILC Therapeutics Signs RandD Partnership With Dechra Pharmaceuticals PLC


    Apr 26, 2023

    Scottish Biotech ILC Therapeutics Sets Sights on Series A and IPO After Recent Investment Round


    Sep 6, 2021

    ILC Therapeutics Announces Successful Completion of £3.5m Funding Round


    May 13, 2021

    ILC Therapeutics Announces Board Changes and Funding Round to Accelerate Covid-19 Drug


    Dec 1, 2020

    UK Biotech Company ILC Therapeutics Announces First International Investment


    For More Press Releases


    Google Analytics Alternative